Comparison of Laughter Yoga and Anti-Anxiety Medication on Anxiety and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome

BACKGROUND Irritable bowel syndrome (IBS) is the most common chronic gastrointestinal (GI) disorder. Patients with IBS usually suffer from anxiety and depression. A combination of psychological approaches and pharmacological treatments can be a significantly effective treatment for IBS. The main objective of the present study was to provide a therapeutic plan based on laughter yoga and anti-anxiety medication, employed for the very first time, and to determine the effectiveness of these treatments on the anxiety and GI symptoms of patients with IBS. METHODS In this randomized, controlled, clinical trial, the participants were 60 patients selected from those who referred to the GI clinic of Vali-asr Hospital (Birjand, Iran) during the study period (April 2017 to March 2017) and were diagnosed as having IBS based on ROME III criteria. The participants were randomly assigned to either the laughter yoga group, the anti-anxiety medication group, or the symptomatic treatment (control) group. Severity levels of anxiety and GI symptoms before and after intervention were determined and compared among these three groups according to approved protocols. RESULTS The severity of IBS symptoms after the interventions was more greatly reduced in the laughter yoga group than in the anti-anxiety medication and control groups (p = 0.006). The severity of anxiety after interventions decreased in all three groups, especially in the yoga treatment group, but the difference was not statistically significant (p = 0.1). CONCLUSION Laughter yoga is more effective than anti-anxiety medication in reducing the GI symptoms of patients with IBS. Therefore, applying laughter yoga along with common pharmacological therapies for patients with IBS might be strongly advised.

Download Full-text

Catastrophizing the Consequences of Gastrointestinal Symptoms in Irritable Bowel Syndrome

Journal of Cognitive Psychotherapy ◽

10.1891/0889-8391.23.2.160 ◽

2009 ◽

Vol 23 (2) ◽

pp. 160-173 ◽

Cited By ~ 15

Author(s):

Melissa G. Hunt ◽

Marina Milonova ◽

Samantha Moshier

Keyword(s):

Irritable Bowel Syndrome ◽

Cognitive Processes ◽

Anxiety Sensitivity ◽

Symptom Severity ◽

Gastrointestinal Symptoms ◽

Control Group ◽

The Social ◽

Gi Symptoms ◽

Functional Implications ◽

Irritable Bowel

This study investigated whether patients with irritable bowel syndrome (IBS) tend to (a) catastrophize the social and functional implications of gastrointestinal (GI) symptoms, and (b) have heightened visceral anxiety sensitivity. IBS patients, Crohn’s disease patients, panic disorder patients, and a normal control group were assessed on GI symptom severity, visceral anxiety sensitivity, and the tendency to catastrophize the implications of GI symptoms. Visceral anxiety sensitivity was associated with more severe GI symptoms for IBS patients but not for Crohn’s patients. IBS patients catastrophized the implications of GI symptoms significantly more than Crohn’s patients and controls but not significantly more than panic patients. Similar to panic patients, but unlike Crohn’s patients, IBS patients engage in maladaptive cognitive processes related to symptom severity. Results suggest that therapeutic focus on reducing visceral anxiety sensitivity and correcting catastrophic beliefs about the social and functional implications of GI symptoms may enhance the efficacy of cognitive interventions for IBS.

Download Full-text

Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms

Scientific Reports ◽

10.1038/s41598-021-87158-2 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

L. Quénéhervé ◽

D. Drui ◽

J. Blin ◽

M. Péré ◽

E. Coron ◽

...

Keyword(s):

Quality Of Life ◽

Irritable Bowel Syndrome ◽

Adrenal Insufficiency ◽

Gastrointestinal Symptoms ◽

Control Group ◽

Non Profit ◽

Acute Adrenal Insufficiency ◽

Irritable Bowel ◽

Rome Iv

AbstractGastrointestinal symptoms are frequent in acute adrenal insufficiency. Although digestive symptoms can significantly reduce quality of life, they are rarely described in patients with treated chronic adrenal insufficiency (CAI). We aimed to characterize digestive symptoms in CAI patients. We used the section pertaining functional bowel disorders of the Rome IV questionnaire. A questionnaire was published on the website of the non-profit patient association “Adrenals” (NPPA of CAI patients) for five months. Information on demographics, characteristics of adrenal insufficiency, digestive symptoms and quality of life was collected. The relatives of CAI patients served as a control group. We analyzed responses of 33 control subjects and 119 patients (68 primary adrenal insufficiency (PAI), 30 secondary adrenal insufficiency (SAI) and 21 congenital adrenal hyperplasia (CAH)). Abdominal pain at least once a week over the past 3 months was reported by 40%, 47% and 33% of patients with PAI, SAI and CAH respectively versus 15% for the controls (p = 0.01). Symptoms were consistent with the Rome IV criteria for irritable bowel syndrome in 27%, 33% and 33% of patients respectively versus 6% for the controls (p < 0.0001). Quality of life was described as poor or very poor in 35%, 57% and 24% of patients respectively versus 5% for the controls (p < 0.0001). In conclusion, digestive symptoms are frequent and incapacitating in CAI patients and similar to symptoms of irritable bowel syndrome in 30% of CAI patients. Assessment and management of digestive symptoms should be considered a priority for physicians treating patients with CAI.

Download Full-text

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report

Journal of Clinical Medicine ◽

10.3390/jcm9082353 ◽

2020 ◽

Vol 9 (8) ◽

pp. 2353

Author(s):

Gian Paolo Caviglia ◽

Alessandra Tucci ◽

Rinaldo Pellicano ◽

Sharmila Fagoonee ◽

Chiara Rosso ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Clinical Response ◽

Bifidobacterium Longum ◽

Gastrointestinal Symptoms ◽

Intestinal Barrier ◽

Response To Therapy ◽

Intestinal Barrier Function ◽

Control Group ◽

Placebo Control ◽

Irritable Bowel

Bifidobacterium longum (B. longum) ES1 is a probiotic strain capable of modulating microbiome composition, anti-inflammatory activity and intestinal barrier function. We investigated the use of B. Longum ES1 in the treatment of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Sixteen patients were treated for 8 or 12 weeks with B. Longum ES1 (1 × 109 CFU/day). Serum zonulin and cytokines were measured at baseline (T0) and at the end of therapy (T1). Clinical response to therapy was assessed by IBS Severity Scoring System. Interleukin (IL)-6, IL-8, IL-12p70 and tumor necrosis factor (TNF) α levels decreased from T0 to T1, irrespective of treatment duration (p < 0.05), while zonulin levels diminished only in patients treated for 12 weeks (p = 0.036). Clinical response was observed in 5/16 patients (31%): 4/8 (50%) treated for 12 weeks and 1/8 (13%) treated for 8 weeks. Abdominal pain improved only in patients treated for 12 weeks (5/8 vs. 0/8, p = 0.025), while stool consistency improved regardless of therapy duration (p < 0.001). In conclusion, the results of this pilot study showed, in IBS-D patients treated for 12 weeks with B. longum ES1, a reduction in the levels of pro-inflammatory cytokines, and intestinal permeability as well as an improvement in gastrointestinal symptoms, but further studies including a placebo-control group are necessary to prove a causal link.

Download Full-text

Effect of Multispecies Probiotic Supplementation on Irritable Bowel Syndrome

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2019/v28i630221 ◽

2019 ◽

pp. 1-9

Author(s):

Saeed Yazdani Ashtiani ◽

Mersad Amery

Keyword(s):

Quality Of Life ◽

Irritable Bowel Syndrome ◽

Abdominal Pain ◽

Therapeutic Option ◽

Intervention Group ◽

Control Group ◽

Controlled Clinical Trial ◽

Probiotic Supplementation ◽

Irritable Bowel

Background: Irritable bowel syndrome (IBS) is a common, chronic and sometimes disabling functional disorder of the gastrointestinal system and its treatment remains as health problem. Thus the aim of this study was to evaluate the Effect of multispecies probiotic supplementation, as a novel and Controversial therapeutic method on Irritable bowel syndrome. Materials and Methods: In this randomized double blind Placebo-controlled clinical trial, 60 patients with IBS were enrolled. The patients were divided randomly into two groups. Patients in intervention group received two 500 mg probiotic capsules (Familact®) and in control group, received two 500 mg placebo capsules daily for 30 consecutive days. The symptoms and quality of life were measured and compared at the beginning and just after the end of study for each case. Results: Results showed the mean score of Abdominal pain after 1 month of treatment in the probiotic group was significantly lower than the control group (1.76 ± 2.04 vs. 2.88 ± 2.25, P=0.049, respectively). While, other symptoms and quality of life did not change significantly (P>0.05). Furthermore, defecation habit and global symptoms improvement was similar after intervention in both groups and we did not observe significant differences in these items (P>0.05). Conclusion: The results of this study showed the beneficial effects of multispecies probiotic supplementation in controlling IBS patients’ abdominal pain. thus it can be prescribed as a therapeutic option in addition to standard therapy and significantly lead to better control of this symptom in the short term.

Download Full-text

Effectiveness of Two Dietary Approaches on the Quality of Life and Gastrointestinal Symptoms of Individuals with Irritable Bowel Syndrome

Journal of Clinical Medicine ◽

10.3390/jcm9010125 ◽

2020 ◽

Vol 9 (1) ◽

pp. 125 ◽

Cited By ~ 1

Author(s):

Maria Margarida Guerreiro ◽

Zélia Santos ◽

Elisabete Carolino ◽

Julieta Correa ◽

Marilia Cravo ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Irritable Bowel Syndrome ◽

Gastrointestinal Symptoms ◽

Standard Diet ◽

Before And After ◽

Irritable Bowel ◽

Fodmap Diet ◽

Third Moment

To evaluate the effectiveness of a low FODMAP (fermentable oligosaccharides, monosaccharaides, disaccharides and polyols) diet in the relief of symptoms and an improvement of the quality of life in individuals with irritable bowel syndrome in comparison to a standard diet according to the British Dietetic Association’s guidelines. A non-randomized clinical trial of adult patients with IBS was compared two diet interventions. An assessment of symptoms, quality of life, and nutritional status was performed before and after the four-week mark of intervention. Individuals from the Low FODMAP Diet (LFD) group were evaluated on a third moment, after the controlled reintroduction of FODMAPs. A total of 70 individuals were divided in two groups: Low FODMAP Diet (LFD; n = 47) and Standard Diet (SD; n = 23). 57 individuals completed the four-week intervention (LFD; n = 39; SD; n = 18). At the completion of four weeks, the symptoms improved in both groups (LFD: p < 0.01; DC: p < 0.05) but LFD led to a higher relief (p < 0.05), primarily with respect to abdominal pain and diarrhoea. Quality of life improved significantly in both groups, with no significant differences between SD vs LFD (p > 0.05). In the LFD group, the relief of symptoms observed at the four-week mark remained constant after reintroduction of FODMAPs. Both interventions seem to be effective for the relief of symptoms and quality of life, however LFD had higher effectiveness in the former. The results with LFD suggest it can be a preferred approach in individuals with diarrhoeal profile.

Download Full-text

Metabolic Profiling of Plasma in Patients with Irritable Bowel Syndrome after a 4-Week Starch- and Sucrose-Reduced Diet

Metabolites ◽

10.3390/metabo11070440 ◽

2021 ◽

Vol 11 (7) ◽

pp. 440

Author(s):

Hans Stenlund ◽

Clara Nilholm ◽

Elin Chorell ◽

Bodil Roth ◽

Mauro D’Amato ◽

...

Keyword(s):

Mass Spectrometry ◽

Irritable Bowel Syndrome ◽

Dietary Intervention ◽

Fatty Acid Biosynthesis ◽

Gastrointestinal Symptoms ◽

Metabolic Effects ◽

Gas Chromatography Mass Spectrometry ◽

Control Group ◽

Chromatography Mass Spectrometry ◽

Irritable Bowel

A 4-week dietary intervention with a starch- and sucrose-restricted diet (SSRD) was conducted in patients with irritable bowel syndrome (IBS) to examine the metabolic profile in relation to nutrient intake and gastrointestinal symptoms. IBS patients were randomized to SSRD intervention (n = 69) or control continuing with their ordinary food habits (n = 22). Food intake was registered and the questionnaires IBS-symptoms severity scale (IBS-SSS) and visual analog scale for IBS (VAS-IBS) were completed. Metabolomics untargeted analysis was performed by gas chromatography mass spectrometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS) in positive and negative ionization modes. SSRD led to marked changes in circulating metabolite concentrations at the group level, most prominent for reduced starch intake and increased polyunsaturated fat, with small changes in the control group. On an individual level, the correlations were weak. The marked reduction in gastrointestinal symptoms did not correlate with the metabolic changes. SSRD was observed by clear metabolic effects mainly related to linoleic acid metabolism, fatty acid biosynthesis, and beta-oxidation.

Download Full-text

Gastrointestinal Symptoms in Diabetes Occur Long Before Diabetic Complications

10.21203/rs.3.rs-594914/v1 ◽

2021 ◽

Author(s):

Hwanseok Jung ◽

Eun-Jung Rhee ◽

Mi Yeon Lee ◽

Jung Ho Park ◽

Dong Il Park ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Functional Dyspepsia ◽

Diabetes Complications ◽

Functional Gastrointestinal Disorders ◽

Gastrointestinal Symptoms ◽

Functional Constipation ◽

Gastrointestinal Disorders ◽

Gi Symptoms ◽

Irritable Bowel ◽

Diabetes Patients

Abstract Background: Gastrointestinal (GI) manifestations are common in patients with diabetes complications such as autonomic neuropathy. However, the prevalence of GI symptoms before the development of diabetes complications remains unclear.Method: We performed an interview survey of functional gastrointestinal disorders in diabetes patients who visited the endocrinology clinic of a general hospital using the ROME III criteria. The investigation consisted of various questions on functional dyspepsia, irritable bowel syndrome, and functional constipation including functional defecation disorder.Results: A total of 509 patients were included in this analysis. The patients were analyzed in three groups, prediabetes patients (n = 115), diabetes patients without neuropathy (n = 275), and diabetes patients with neuropathy (n = 119). The prevalence of gastrointestinal symptoms in prediabetes patients, diabetes patients without neuropathy, and diabetes patients with neuropathy was estimated at 16.52%, 27.27%, and 23.53% for functional dyspepsia; 8.7%, 11.68%, and 16.81% for irritable bowel syndrome; and 8.85%, 11.85%, and 15.25% for functional constipation. In the subgroup analysis, postprandial distress syndrome symptoms such as postprandial fullness and early satiation were more prevalent than epigastric pain symptoms. In the constipation group, pelvic outlet obstruction symptoms such as the sensation of anorectal obstruction or blockage and manual maneuvers to facilitate defecation were more frequently observed than slow transit constipation symptomsConclusions: The prevalence of functional gastrointestinal disorders increased with diabetes severity. Diabetes-related GI symptoms appeared long before the diabetes complications

Download Full-text

Diagnostic Utility of Beta 2 Microglobulin in Patients with Irritable Bowel Syndrome and Ulcerative Colitis

10.51429/ejmm30213 ◽

2021 ◽

Vol 30 (2) ◽

pp. 89-97

Author(s):

Mohamed Eltabbakh ◽

Waheed Abd Almonsef ◽

Shimaa Y. Kamel ◽

Soha Abuelela ◽

AL-Shaimaa M. AL-Tabbakh ◽

...

Keyword(s):

Ulcerative Colitis ◽

Irritable Bowel Syndrome ◽

Inactive Disease ◽

Control Group ◽

University Hospitals ◽

Roc Curve Analysis ◽

Inflammatory Conditions ◽

The Difference ◽

Irritable Bowel ◽

Beta 2 Microglobulin

Background: Inflammatory bowel disease (IBD) is a chronically relapsing disease. It includes ulcerative colitis (UC) and crohn's disease (CD). Symptoms of IBD could be conflicting sometimes with irritable bowel syndrome (IBS) of diarrheal type. The ideal marker for IBD/IBS diagnosis has not yet been identified. B2 microglobulin (B2-M) is a low molecular weight protein released by activated T and B lymphocytes. It has been shown to increase in several chronic inflammatory conditions. Objectives: Assessment of the diagnostic role of (B2-M) in IBS cases presented with diarrhea (IBS-D type) and UC cases. Methodology: This case control study was conducted at Gastroenterology Unit in Tropical Medicine Department, Ain- Shams University Hospitals, Cairo, Egypt. Forty patients with UC, and twenty patients with IBS in addition to twenty healthy persons as control were included. Results: There was a higher mean of B2-M values among U.C group (1.93)(mean B2-M in Active UC was 2.26 and 1.61 in inactive disease) compared to the other two groups(1.51 in IBS and 1.43 in control group) and the difference was highly statistically significant(P=0.000).Using ROC curve analysis of different cut off values of (B2-M) for detection of UC cases among IBS cases, we found that at a cut off value of <1.5 , we got sensitivity, specificity, PPV, NPV and accuracy of 75 %, 70 %, 83.3%, 58.3 %, and 0.753% respectively and this was the best cut off value. Conclusion: B2-M level may have a diagnostic and differentiating utility between UC cases and IBS-D type as well as a potential indicator of disease activation in UC patients.

Download Full-text

A Randomized Trial of Yoga for Adolescents with Irritable Bowel Syndrome

Pain Research and Management ◽

10.1155/2006/731628 ◽

2006 ◽

Vol 11 (4) ◽

pp. 217-224 ◽

Cited By ~ 106

Author(s):

Leora Kuttner ◽

Christine T Chambers ◽

Janine Hardial ◽

David M Israel ◽

Kevan Jacobson ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Functional Disability ◽

Randomized Study ◽

Gastrointestinal Symptoms ◽

Control Group ◽

Wait List ◽

Wait List Control Group ◽

Wait List Control ◽

Yoga Intervention ◽

Irritable Bowel

BACKGROUND: Adolescents with irritable bowel syndrome (IBS) frequently experience interference with everyday activities. Mind-body approaches such as yoga have been recommended as interventions for patients with IBS. Despite promising results among adult samples, there have been limited studies exploring the efficacy of yoga with pediatric patients.OBJECTIVE: To conduct a preliminary randomized study of yoga as treatment for adolescents with IBS.METHODS: Twenty-five adolescents aged 11 to 18 years with IBS were randomly assigned to either a yoga or wait list control group. Before the intervention, both groups completed questionnaires assessing gastrointestinal symptoms, pain, functional disability, coping, anxiety and depression. The yoga intervention consisted of a 1 h instructional session, demonstration and practice, followed by four weeks of daily home practice guided by a video. After four weeks, adolescents repeated the baseline questionnaires. The wait list control group then received the yoga intervention and four weeks later completed an additional set of questionnaires.RESULTS: Adolescents in the yoga group reported lower levels of functional disability, less use of emotion-focused avoidance and lower anxiety following the intervention than adolescents in the control group. When the pre- and postintervention data for the two groups were combined, adolescents had significantly lower scores for gastrointestinal symptoms and emotion-focused avoidance following the yoga intervention. Adolescents found the yoga to be helpful and indicated they would continue to use it to manage their IBS.CONCLUSIONS: Yoga holds promise as an intervention for adolescents with IBS.

Download Full-text

Irregular Dietary Habits with a High Intake of Cereals and Sweets Are Associated with More Severe Gastrointestinal Symptoms in IBS Patients

Nutrients ◽

10.3390/nu11061279 ◽

2019 ◽

Vol 11 (6) ◽

pp. 1279 ◽

Cited By ~ 6

Author(s):

Clara Nilholm ◽

Ewa Larsson ◽

Bodil Roth ◽

Rita Gustafsson ◽

Bodil Ohlsson

Keyword(s):

Irritable Bowel Syndrome ◽

Dietary Habits ◽

Eating Habits ◽

Gastrointestinal Symptoms ◽

Well Being ◽

Irritable Bowel Syndrome Symptom ◽

Dietary Advice ◽

Blood Levels ◽

Gi Symptoms ◽

Irritable Bowel

Dietary advice constitutes one of the first choices of treatment for irritable bowel syndrome (IBS). We have recognized an increased prevalence of sucrase-isomaltase (SI) gene variants in IBS patients, possibly rendering starch- and sucrose-intolerance. The aims were to examine participants’ dietary habits at baseline, to correlate habits with gastrointestinal (GI) symptoms and blood levels of minerals and vitamins, and to examine the effect of a starch- and sucrose-reduced diet (SSRD) on GI symptoms. In the study 105 IBS patients (82 women, 46.06 ± 13.11 years), irritable bowel syndrome-symptom severity scale (IBS-SSS)>175, were randomized to SSRD for 2 weeks or continued ordinary eating habits. Blood samples, visual analog scale for irritable bowel syndrome (VAS-IBS), IBS-SSS, and 4-day food diaries were collected at baseline and after 2 weeks. Patients with irregular dietary habits exhibited higher IBS-SSS than patients with regular habits (p = 0.029). Women already on a diet had lower ferritin levels than others (p = 0.029). The intervention led to 66.3% of patients being responders, with differences in the change of IBS-SSS (p < 0.001), abdominal pain (p = 0.001), diarrhea (p = 0.002), bloating and flatulence (p = 0.005), psychological well-being (p = 0.048), and intestinal symptoms’ influence on daily life (p < 0.001), compared to controls. Decreased intake of cereals and sweets/soft drinks correlated with decreased scores.

Download Full-text